Accepted Papers

Accelerating Prototype-Based Drug Discovery using Conditional Diversity Networks

Shahar Harel (Technion); Kira Radinsky (Technion – Israel Institute of Technology)

Designing a new drug is a lengthy and expensive process. As the space of potential molecules is very large (10 23 - 10 60 ), a common technique during drug discovery is to start from a molecule which already has some of the desired properties. An interdisciplinary team of scientists generates hypothesis about the required changes to the prototype. In this work, we develop an algorithmic unsupervised-approach that automatically generates potential drug molecules given a prototype drug. We show that the molecules generated by the system are valid molecules and significantly different from the prototype drug. Out of the compounds generated by the system, we identified 35 FDA-approved drugs. As an example, our system generated Isoniazid - one of the main drugs for Tuberculosis. The system is currently being deployed for use in collaboration with pharmaceutical companies to further analyze the additional generated molecules.

Promotional Video

How can we assist you?

We'll be updating the website as information becomes available. If you have a question that requires immediate attention, please feel free to contact us. Thank you!


If you are experiencing any issue related to registrations (confirmation, payment problem etc.) or have any questions regarding registrations, please do not submit this form. Please send an email to Kelly Hughes (khughes@executivevents.com) or call 1.888.526.1242 or 303.530.4683.